Preferences help
enabled [disable] Abstract
Number of results
2015 | 5 | 1 | A5-A10
Article title

Adriamycin cardiomyopathy with congestive heart failure, cardiogenic shock and emergency heart transplant: 30-year follow up

Title variants
Languages of publication
Doxorubicin chemotherapeutic agent is widely utilized for many types of cancers since the late 1960s. Cardiomyopathy is a well-known side effect of doxorubicin often limiting its use. In many cases doxorubicin cardiomyopathy can lead to end stage cardiac failure requiring heart transplantation. The quality of life of heart transplant patients is exceptional with most patients being able to continue normal activities following recovery. There has been significant advancement in cardiac transplantation since it was first attempted in 1967 in Cape Town, South Africa. Drugs such as cyclosporine played an important role in preventing graft failure and prolonging patient survival. Cardiac transplant can extend a patients’ life by over a decade. The patient in this case, Mr. Glen Frank Spurling, has survived 30 years following his cardiac transplant surgery. In this article an overview of doxorubicin cardiotoxicity, cardiac transplantation, and an interview with Mr. Glen Frank Spurling is presented.
Physical description
  • Saba University School of Medicine
  • Morsani School of Medicine; University of South Florida
  • Davis MK, Hunt SA. State of the art: Cardiac transplantation. Trends in cardiovascular medicine 2014; 24(8): 341-349.
  • Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology 2010; 115(2): 155.
  • Weisse AB. Cardiac surgery: a century of progress. Texas Heart Institute Journal 2011; 38(5): 486.
  • Brink JG, Hassoulas J. The first human heart transplant and further advances in cardiac transplantation at Groote Schuur Hospital and the University of Cape TownWith reference to: The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town: historical review article. Cardiovascular journal of Africa 2009; 20(1): 30-35.
  • DiBardino DJ. The history and development of cardiac transplantation. Texas Heart Institute Journal 1999; 26(3): 198.
  • De Salvatore S, Segreto A, Chiusaroli A et al. The Role of Xenotransplantation in Cardiac Transplantation. Journal of cardiac surgery 2015; 30(1): 111-116.
  • Alraies MC, Eckman P. Adult heart transplant: indications and outcomes. Journal of thoracic disease 2014; 6(8): 1120.
  • Taylor DO, Edwards LB, Boucek MM et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report – 2007. The Journal of heart and lung transplantation 2007; 26(8): 769-781.
  • Pollack A, Nazif T, Mancini D, Weisz G. Detection and imaging of cardiac allograft vasculopathy. JACC: Cardiovascular Imaging 2013; 6(5): 613-623.
  • Ferencik M, Brady TJ, Hoffmann U. Computed tomography imaging of cardiac allograft vasculopathy. Journal of cardiovascular computed tomography 2012; 6(4): 223-231.
  • Yagdi T, Sharples L, Tsui S et al. Malignancy after Heart Transplantation: Analysis of 24-Year Experience at a Single Center. Journal of cardiac surgery 2009; 24(5): 572-579.
  • Pollack A, Nazif T, Mancini D, Weisz G. Detection and imaging of cardiac allograft vasculopathy. JACC: Cardiovascular Imaging 2013; 6(5): 613-623.
  • FDA Approves the SynCardia Total Artificial Heart for Destination Therapy Study. [(2015, January 6). Retrieved March 2, 2015, from].
  • Lenneman AJ, Wang L, Wigger M et al. Heart Transplant Survival Outcomes for Adriamycin Dilated Cardiomyopathy. The American Journal of Cardiology 2013; 111(4): 609-612.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.